EUVIMEDEUVIMED entdecken
Crossref

Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer: A Retrospective Study

LinHong Cui, KunXiang Cheng, MingXin Cui, XiaoMei Li

Oncology · 2025

DOI: 10.1159/000543556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von LinHong Cui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, The Second Medical Centre of Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitor-related pneumonitis (ICI-P) is a life-threatening complication, limiting immune checkpoint inhibitors (ICIs) clinical application in non-small cell lung cancer (NSCLC). But risk factors for developing ICI-P have not been well defined.

Methods

This study employed a retrospective analysis method. Following approval from the Ethics Committee of Chinese PLA General Hospital, we retrieved patient information on NSCLC registered in the hospital’s PRIDE workstation, selecting patients who received treatment with ICIs from January 1, 2018, to September 30, 2023. Complete medical records of patients were collected and verified. Logistic regression analysis was used to identify independent high-risk factors for the occurrence of ICI-P.

Results

A total of 753 patients with NSCLC who received treatment with ICIs were included, with a mean age of (63 ± 9.5) years. A total of 102 patients diagnosed with ICI-P were identified, resulting in an incidence rate of 13.5%. Development of ICI-P was independently associated with history of interstitial lung disease (ILD) (OR, 3.85; CI, 1.99–7.46; p < 0.001), prior thoracic radiotherapy (OR, 2.65; CI, 1.56–4.48; p < 0.001), concurrent thoracic radiotherapy (OR, 3.56; CI, 1.69–7.47; p < 0.001) and treatment with programmed cell death 1 (PD-1) inhibitors compared with programmed death-ligand 1 (PD-L1) inhibitors (OR, 3.54; CI, 1.05–11.98; p = 0.04).

Conclusion

Independent risk factors for ICI-P occurrence included the history of ILD, previous chest radiotherapy, concurrent chest radiotherapy, and the use of PD-1 inhibitors (compared to non-PD-1 inhibitors). Specialty assessment of ILD before treatment and cautious use of ICIs in radiotherapy patients, represent feasible strategies to prevent the occurrence of ICI-P.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsPneumoniaHumansRetrospective StudiesMiddle AgedMaleFemaleRisk FactorsAged

Stichwörter der Autor:innen

CarcinomaImmune checkpoint inhibitorsNon-small-cell lungPneumonitisRisk factors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Geriatric Medicine, The Second Medical Centre of Chinese PLA General Hospital, Beijing, China.
  • Graduate School, Chinese PLA General Hospital, Beijing, China.

Zitieren

APA

Cui, L., Cheng, K., Cui, M., & Li, X. (2025). Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer: A Retrospective Study. Oncology. https://doi.org/10.1159/000543556

Vancouver

Cui L, Cheng K, Cui M, Li X. Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer: A Retrospective Study. Oncology. 2025. doi:10.1159/000543556

BibTeX
@article{Cui2025,
  author = {Cui, LinHong and Cheng, KunXiang and Cui, MingXin and Li, XiaoMei},
  title = {Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer: A Retrospective Study},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000543556}
}
Kostenlos starten →